** AbbVie ABBV.N forecast 2025 profit above estimates on Friday, as strong sales of its newer immunology drugs Skyrizi and Rinvoq make up for a steep decline in those of Humira, its flagship rheumatoid arthritis drug, that is now facing stiff competition
** Median PT of 29 brokerages covering the stock is $205.50 - LSEG data
ROBUST PIPELINE TO FUEL GROWTH
** J.P.Morgan ("overweight") says "more broadly on the story, we see ABBV as well-positioned with no major LOEs (loss of exclusivity) until the mid 2030s, ongoing upside from Skyrizi/Rinvoq, and balance sheet capacity for additional BD to address growth in the 2030s"
** Morgan Stanley ("overweight", PT: $239) says the long-term outlook for its newer immunology drugs, Skyrizi and Rinvoq, continues to bolster confidence in ABBV's long-term growth profile
** Truist Securities ("buy", PT: $217) says "ABBV continues to deliver strong growth into the longer-term and sees no other LOE for the rest of the decade, we see a clear growth trajectory into 2029"
** Morningstar (fair value: $184) says ABBV's transition to more effective immunology products in the face of Humira sales erosion demonstrates its strong competitive advantage
(Reporting by Joel Jose in Bengaluru)
((joeljose@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.